Antitrypanosomal Lead Discovery: Identification of a Ligand-Efficient Inhibitor of Trypanosoma cruzi CYP51 and Parasite Growth
- 13 March 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (6) , 2556-2567
Abstract
Chagas disease is caused by the intracellular protozoan parasite Trypanosomal cruzi, and current drugs are lacking in terms of desired safety and efficacy profiles. Following on a recently reported high-throughput screening campaign, we have explored initial structure–activity relationships around a class of imidazole-based compounds. This profiling has uncovered compounds 4c (NEU321) and 4j (NEU704), which are potent against in vitro cultures of T. cruzi and are greater than 160-fold selective over host cells. We report in vitro drug metabolism and properties profiling of 4c and show that this chemotype inhibits the T. cruzi CYP51 enzyme, an observation confirmed by X-ray crystallographic analysis. We compare the binding orientation of 4c to that of other, previously reported inhibitors. We show that 4c displays a significantly better ligand efficiency and a shorter synthetic route over previously disclosed CYP51 inhibitors, and should therefore be considered a promising lead compound for further optimization.Keywords
This publication has 21 references indexed in Scilit:
- Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from TipifarnibAntimicrobial Agents and Chemotherapy, 2012
- Activity In Vivo of Anti-Trypanosoma cruzi Compounds Selected from a High Throughput ScreeningPLOS Neglected Tropical Diseases, 2011
- Substrate Preferences and Catalytic Parameters Determined by Structural Characteristics of Sterol 14α-Demethylase (CYP51) from Leishmania infantumJournal of Biological Chemistry, 2011
- Structural basis for conservation in the CYP51 familyBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2011
- Structural Insights into Inhibition of Sterol 14α-Demethylase in the Human Pathogen Trypanosoma cruziJournal of Biological Chemistry, 2010
- Second Generation Analogues of the Cancer Drug Clinical Candidate Tipifarnib for Anti-Chagas Disease Drug DiscoveryJournal of Medicinal Chemistry, 2010
- Crystal Structures of Trypanosoma brucei Sterol 14α-Demethylase and Implications for Selective Treatment of Human InfectionsJournal of Biological Chemistry, 2010
- Identification of Three Classes of Heteroaromatic Compounds with Activity against Intracellular Trypanosoma cruzi by Chemical Library ScreeningPLOS Neglected Tropical Diseases, 2009
- Rational Modification of a Candidate Cancer Drug for Use Against Chagas DiseaseJournal of Medicinal Chemistry, 2009
- Sterol 14α-Demethylase as a Potential Target for Antitrypanosomal Therapy: Enzyme Inhibition and Parasite Cell GrowthChemistry & Biology, 2007